Abstract:Benign epilepsy with centrotemporal spikes (BECTS) is the most common epilepsy syndrome and the aetiology is unclear, but recent epidemiological research has suggested that it is a neurological disorder with a strong genetic basis.1 We recruited a pair of twins, only one of which exhibited BECTS. The proband was an 11-year-old girl diagnosed with BECTS. Her first reported symptoms were seizures at the age of 9 years and sudden loss of consciousness followed by tonic–clonic movements of the extremities lasting 10 min. Electroencephalogram showed bilateral centrotemporal spikes with electrical status epilepticus during sleep. Whole-exome sequencing was performed on the proband, her normal twin sister and their parents. A de novo heterozygous variant in KCNT1, p.R1061Q, was found, which was further confirmed by Sanger sequencing. The KCNT1 gene belongs to a large family of genes encoding potassium channels. The missense variant p.R1061Q leads to a change from arginine to glutamic acid at residue 1061, and was predicted to damage the protein function of KCNT1. The analysis of the twin sisters and the family-based whole-exome sequencing helped us to quickly narrow down the list of candidate variants associated with BECTS. KCNT1 mutation can lead to different forms of epilepsy,2 which may be related to the location of the mutation. We found that the mutation was located at the 1061st amino acid near the C-terminus, which has not previously been reported in epilepsy patients. However, the 1106th amino acid, or c.3317G>A, p.Arg1106Gln, was reported to be associated with Brugada syndrome, a cardiac disorder comorbidity for epilepsy.3 Moreover, Tiron et al. found that long QT syndrome, a congenital disorder characterised by prolongation of the QT interval on electrocardiograms, coexists with epilepsy, which is associated with mutation in KCNQ1, which like KCNT1 belongs to the potassium ion channel group of genes.2 Understanding the patient's genetic background should be beneficial for precisely choosing the most appropriate treatment. Studies have shown the promise of quinidine as a targeted intervention for patients with KCNT mutations.4 Further clinical trials of quinidine treatment in patients with KCNT1 mutations in BECTS are also necessary, and in-depth functional studies will be necessary to determine the pathogenic role of KNCT1 in BECTS. This project was supported by the National Natural Science Foundation of China (programme nos. 81500974, 81701351, 81471329 and 81720108018) and Shenzhen Science Technology and Innovation Commission (programme nos. JCYJ20160429174706491 and JCYJ20170413093358429).

Case report: Marked electroclinical improvement by fluoxetine treatment in a patient with KCNT1-related drug-resistant focal epilepsy

Autosomal Dominant Sleep-Related Hypermotor Epilepsy Associated with a Novel Mutation of KCNT1.

A novel KCNT1 mutation in a Chinese family with severe autosomal-dominant nocturnal frontal lobe epilepsy

Long-term follow-up of vagus nerve stimulation in drug-resistant KCNT1-related epilepsy: a case presentation

Phenotypic and functional assessment of two novel KCNQ2 gain-of-function variants Y141N and G239S and effects of amitriptyline treatment

KCNT1-related epilepsy: An international multicenter cohort of 27 pediatric cases

Functional consequences of a KCNT1 variant associated with status dystonicus and early-onset infantile encephalopathy

Distinct epilepsy phenotypes and response to drugs in KCNA1 gain‐ and loss‐of function variants

The epilepsy phenotype of KCNK4-related neurodevelopmental disease

In Silico Assisted Identification, Synthesis, and In Vitro Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 Channel

Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy

KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties

A novel KCNQ3 mutation in familial epilepsy with focal seizures and intellectual disability

Treatment Responsiveness in KCNT1-Related Epilepsy

Impressive efficacy of the ketogenic diet in a KCNQ2 encephalopathy infant: a case report and exhaustive literature review

Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy

Identification of a novel KCNT2 variant in a family with developmental and epileptic encephalopathies: a case report and literature review

Antisense oligonucleotide therapy for KCNT1 encephalopathy

The Epilepsy of Infancy With Migrating Focal Seizures: Identification of de novo Mutations of the KCNT2 Gene That Exert Inhibitory Effects on the Corresponding Heteromeric KNa1.1/KNa1.2 Potassium Channel

Whole‐Exome Sequencing Revealing De Novo Heterozygous Variant OF KCNT1 in a Twin Discordant for Benign Epilepsy with Centrotemporal Spikes

Case Report: Causative De Novo Variants of KCNT2 for Developmental and Epileptic Encephalopathy